Aims: To describe cannabis ‘vaping' with electronic cigarettes (e-cigarettes) or electronic vaporizers (e-vaporizers). Methods: Internet survey in 2013-2014. Participants were 11 people who ‘vaped' cannabis with e-cigarettes and 44 people who vaped cannabis with e-vaporizers, enrolled online. Results: Most participants were men (78%). They had used e-cigarettes for 6 days and e-vaporizers for 50 days on average to vape cannabis. Current users of e-cigarettes vaped cannabis on 2 days/week versus 6 days/week for users of e-vaporizers. In these devices, they mostly inserted cannabis buds and oil rather than hashish or wax/butane honey oil. Dual users, who both smoked and vaped cannabis, currently smoked 5 joints/week compared to 14 joints/week before they started to vape cannabis (p = 0.004). Half the participants (45%) reported that vaping cannabis helped them stop or reduce their total cannabis use, 37% that it had no impact on their cannabis use, and 6% that it increased it. Vaping cannabis was perceived as healthier and more discrete than smoking it (less odor). Disadvantages included dry mouth and fewer positive cannabis effects. Conclusions: Cannabis vaping via e-cigarettes or e-vaporizers is an infrequent behavior that was previously almost undocumented. E-cigarettes do not appear to be a very appealing way to use cannabis.

Etter JF, Bullen C, Flouris AD, Laugesen M, Eissenberg T: Electronic nicotine delivery systems: a research agenda. Tob Control 2011;20:243-248.
Magic Flight. (accessed on 18 February 2014).
Ploom. (accessed on 18 February 2014).
Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL: Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 2007;82:572-578.
Young B: Amateur hash-oil production, explosions bound to continue. The Seattle Times 2014. (accessed on 18 February 2014).
Dry herb vaporizer pen. http://www.e-ciga max-i-p-544.html (accessed on 18 February 2014).
Hazekamp A, Ruhaak R, Zuurman L, Van Gerven J, Verpoorte R: Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 2006;95:1308-1317.
Malouff JM, Rooke SE, Copeland J: Experiences of marijuana-vaporizer users, Subst Abus 2014;35:127-128.
Earleywine M, Barnwell SS: Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduct J 2007;4:11.
Van Dam NT, Earleywine M: Pulmonary function in cannabis users: support for a clinical trial of the vaporizer. Int J Drug Policy 2010;21:511-513.
Pomahacova B, Van der Kooy F, Verpoorte R: Cannabis smoke condensate III: the cannabinoid content of vaporised Cannabis sativa. Inhal Toxicol 2009;21:1108-1112.
Fischedick J, Van der Kooy F, Verpoorte R: Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor. Chem Pharm Bull (Tokyo) 2010;58:201-207.
Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F: The medicinal use of cannabis and cannabinoids - an international cross-sectional survey on administration forms. J Psychoactive Drugs 2013;45:199-210.
Etter JF, Bullen C: Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction 2011;106:2017-2028.
Etter JF, Bullen C: A longitudinal study of electronic cigarette users. Addict Behav 2014;39:491-494.
Wang J, Etter JF: Administering an effective health intervention for smoking cessation online: the international users of Stop-Tabac. Prev Med 2004;39:962-968.
Etter JF, Bullen C: Saliva cotinine levels in users of electronic cigarettes. Eur Respir J 2011;38:1219-1220.
Jarvik ME, Madsen DC, Olmstead RE, Iwamoto-Schaap PN, Elins JL, Benowitz NL: Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav 2000;66:553-558.
McCauley L, Markin C, Hosmer D: An unexpected consequence of electronic cigarette use. Chest 2012;141:1110-1113.
Jensen G, Bertelotti R, Greenhalgh D, Palmieri T, Maguina P: Honey oil burns: a growing problem. J Burn Care Res 2014, Epub ahead of print.
Patton GC, Coffey C, Carlin JB, Sawyer SM, Lynskey M: Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence, Addiction 2005;100:1518-1525.
Stinson FS, Ruan WJ, Pickering R, Grant BF: Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 2006;36:1447-1460.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.